{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:13:53Z","timestamp":1794266033952,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Zhejiang Province Basic Public Welfare Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biomaterials.2024.122710","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T21:31:51Z","timestamp":1721597511000},"page":"122710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy"],"prefix":"10.1016","volume":"311","author":[{"given":"Jilong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2308-7284","authenticated-orcid":false,"given":"Yikai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshou","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5137-8615","authenticated-orcid":false,"given":"Junjie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biomaterials.2024.122710_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/734515","article-title":"Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy","volume":"2014","author":"Escors","year":"2014","journal-title":"New J Sci"},{"issue":"33","key":"10.1016\/j.biomaterials.2024.122710_bib3","doi-asserted-by":"crossref","first-page":"39003","DOI":"10.1021\/acsami.1c08290","article-title":"Combination of chidamide-mediated epigenetic modulation with immunotherapy: boosting tumor immunogenicity and response to PD-1\/PD-L1 blockade","volume":"13","author":"Tu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122710_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122710_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122710_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint blockade: a focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biomaterials.2024.122710_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122710_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","article-title":"Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities","volume":"129","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"26","key":"10.1016\/j.biomaterials.2024.122710_bib9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122710_bib10","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1021\/acsnano.1c09048","article-title":"Nitric oxide induces immunogenic cell death and potentiates cancer immunotherapy","volume":"16","author":"Jiang","year":"2022","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41565-023-01498-w","article-title":"Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours","volume":"19","author":"Wang","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122710_bib12","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Explorations"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122710_bib13","article-title":"Biomimetic and bioinspired nano-platforms for cancer vaccine development","volume":"3","author":"Feng","year":"2023","journal-title":"Explorations"},{"issue":"24","key":"10.1016\/j.biomaterials.2024.122710_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.21037\/atm-20-2920","article-title":"Alterations of DNA damage repair in cancer: from mechanisms to applications","volume":"8","author":"Jiang","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122710_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300121","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2024.122710_bib17","article-title":"Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2024.122710_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fonc.2020.00480","article-title":"Tumor mutation burden correlates with efficacy of chemotherapy\/targeted therapy in advanced non-small cell lung cancer","volume":"10","author":"Lin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122710_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101788","article-title":"Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies","volume":"38","author":"Vryza","year":"2023","journal-title":"Transl Oncol"},{"issue":"9","key":"10.1016\/j.biomaterials.2024.122710_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the international association for the study of lung cancer pathology committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122710_bib21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.trecan.2021.08.005","article-title":"Tumor mutational burden and immunotherapy in gliomas","volume":"7","author":"Merchant","year":"2021","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122710_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cllc.2018.09.008","article-title":"Association of tumor mutational burden with DNA repair mutations and response to anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer","volume":"20","author":"Chae","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.biomaterials.2024.122710_bib23","article-title":"Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB measurement in clinical practice: considerations on assay requirements","volume":"4","author":"Buttner","year":"2019","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s40425-019-0584-2","article-title":"Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates","volume":"7","author":"Wang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6280","key":"10.1016\/j.biomaterials.2024.122710_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122710_bib27","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1021\/acsabm.2c00343","article-title":"Spatio-temporal controlled gene-chemo drug delivery in a DNA nanocomplex to overcome multidrug resistance of cancer cells","volume":"5","author":"Zhao","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122710_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.biomaterials.2024.122710_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122710_bib30","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"21","key":"10.1016\/j.biomaterials.2024.122710_bib32","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122710_bib33","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M312215200","article-title":"Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains","volume":"279","author":"Ng","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122710_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-020-00874-6","article-title":"Participation of the ATR\/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer","volume":"13","author":"Gralewska","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122710_bib35","first-page":"1","article-title":"High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas","volume":"15","author":"Mei","year":"2020","journal-title":"J. D. p."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122710_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biomaterials.2024.122710_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122710_bib38","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1021\/jacs.4c00451","article-title":"Multicomponent synthesis of imidazole-based ionizable lipids for highly efficient and spleen-selective messenger RNA delivery","volume":"146","author":"Dong","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122710_bib39","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1021\/acs.nanolett.4c01458","article-title":"Helper lipid-enhanced mRNA delivery for treating metabolic dysfunction-associated fatty liver disease","volume":"24","author":"Guo","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.biomaterials.2024.122710_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.actbio.2024.03.031","article-title":"Immunometabolic reprogramming of macrophages with inhalable CRISPR\/Cas9 nanotherapeutics for acute lung injury intervention","volume":"181","author":"Huang","year":"2024","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122710_bib41","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1007\/s12274-022-5205-6","article-title":"Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Nano Res."},{"key":"10.1016\/j.biomaterials.2024.122710_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122710_bib43","first-page":"986","article-title":"Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy","volume":"41","author":"Gao","year":"2020","journal-title":"J. A. P. S."},{"key":"10.1016\/j.biomaterials.2024.122710_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: applications for cancer immunotherapy","volume":"97","author":"Showalter","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.biomaterials.2024.122710_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294434","article-title":"Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system","volume":"14","author":"Calvillo-Rodriguez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2024.122710_bib46","volume":"vol. 39","author":"Shui","year":"2023"},{"key":"10.1016\/j.biomaterials.2024.122710_bib47","first-page":"2261","article-title":"Cancer cell membrane-coated gambogic acid nanoparticles for effective anticancer vaccination by activating dendritic cells","author":"Huang","year":"2023","journal-title":"J. I. J. o. N."},{"issue":"44","key":"10.1016\/j.biomaterials.2024.122710_bib48","article-title":"Activated natural killer cells\u2010dependent dendritic cells recruitment and maturation by responsive nanogels for targeting pancreatic","volume":"18","author":"Deng","year":"2022","journal-title":"Cancer Immunotherapy"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224002448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224002448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:08:36Z","timestamp":1728518916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224002448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":48,"alternative-id":["S0142961224002448"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122710","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122710"}}